Greg Harrison
Stock Analyst at Scotiabank
(3.35)
# 923
Out of 4,944 analysts
99
Total ratings
48.68%
Success rate
3.29%
Average return
Main Sectors:
Stocks Rated by Greg Harrison
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TVTX Travere Therapeutics | Maintains: Sector Outperform | $30 → $31 | $18.05 | +71.75% | 6 | Aug 7, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Sector Outperform | $22 → $20 | $12.50 | +60.00% | 2 | Aug 6, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Sector Outperform | $55 → $57 | $50.38 | +13.14% | 7 | Aug 6, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Sector Perform | $442 → $438 | $395.92 | +10.63% | 7 | Aug 5, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Sector Outperform | $342 → $450 | $432.52 | +4.04% | 6 | Aug 1, 2025 | |
| AGIO Agios Pharmaceuticals | Maintains: Sector Outperform | $71 → $65 | $36.61 | +77.55% | 7 | Jul 28, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $9 → $4 | $3.09 | +29.45% | 8 | Jul 25, 2025 | |
| GOSS Gossamer Bio | Initiates: Sector Outperform | $11 | $1.97 | +458.38% | 1 | Jul 14, 2025 | |
| ARCT Arcturus Therapeutics Holdings | Maintains: Sector Outperform | $32 → $35 | $19.21 | +82.20% | 2 | Jul 2, 2025 | |
| UTHR United Therapeutics | Maintains: Neutral | $321 → $315 | $309.72 | +1.70% | 4 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $65 → $55 | $21.97 | +150.34% | 3 | Jun 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $36 → $37 | $25.20 | +46.83% | 6 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $41 → $26 | $13.90 | +87.05% | 6 | May 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Perform | $28 → $20 | $26.58 | -24.76% | 4 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sector Perform | $4 → $1.5 | $1.43 | +4.90% | 3 | May 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Sector Outperform | $40 | $17.52 | +128.31% | 5 | Mar 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sector Outperform | $73 → $75 | $61.10 | +22.75% | 4 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sector Outperform | $18 | $11.01 | +63.49% | 1 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $89 → $91 | $11.00 | +727.27% | 2 | Jun 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $9 → $12 | $16.91 | -29.04% | 3 | May 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $5 → $1.5 | $0.54 | +177.98% | 1 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $39 | $13.56 | +187.61% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $15 | $3.08 | +387.01% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 | $4.27 | -29.74% | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $70 | $1.54 | +4,445.45% | 1 | Sep 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $67 → $54 | $17.19 | +214.14% | 1 | Mar 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $270 → $90 | $25.72 | +249.92% | 5 | Mar 14, 2022 |
Travere Therapeutics
Aug 7, 2025
Maintains: Sector Outperform
Price Target: $30 → $31
Current: $18.05
Upside: +71.75%
Ocular Therapeutix
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $22 → $20
Current: $12.50
Upside: +60.00%
BridgeBio Pharma
Aug 6, 2025
Maintains: Sector Outperform
Price Target: $55 → $57
Current: $50.38
Upside: +13.14%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Sector Perform
Price Target: $442 → $438
Current: $395.92
Upside: +10.63%
Alnylam Pharmaceuticals
Aug 1, 2025
Maintains: Sector Outperform
Price Target: $342 → $450
Current: $432.52
Upside: +4.04%
Agios Pharmaceuticals
Jul 28, 2025
Maintains: Sector Outperform
Price Target: $71 → $65
Current: $36.61
Upside: +77.55%
Rocket Pharmaceuticals
Jul 25, 2025
Downgrades: Neutral
Price Target: $9 → $4
Current: $3.09
Upside: +29.45%
Gossamer Bio
Jul 14, 2025
Initiates: Sector Outperform
Price Target: $11
Current: $1.97
Upside: +458.38%
Arcturus Therapeutics Holdings
Jul 2, 2025
Maintains: Sector Outperform
Price Target: $32 → $35
Current: $19.21
Upside: +82.20%
United Therapeutics
Jun 11, 2025
Maintains: Neutral
Price Target: $321 → $315
Current: $309.72
Upside: +1.70%
Jun 2, 2025
Maintains: Sector Outperform
Price Target: $65 → $55
Current: $21.97
Upside: +150.34%
May 28, 2025
Maintains: Sector Outperform
Price Target: $36 → $37
Current: $25.20
Upside: +46.83%
May 12, 2025
Maintains: Sector Outperform
Price Target: $41 → $26
Current: $13.90
Upside: +87.05%
May 8, 2025
Maintains: Sector Perform
Price Target: $28 → $20
Current: $26.58
Upside: -24.76%
May 8, 2025
Downgrades: Sector Perform
Price Target: $4 → $1.5
Current: $1.43
Upside: +4.90%
Mar 10, 2025
Upgrades: Sector Outperform
Price Target: $40
Current: $17.52
Upside: +128.31%
Mar 3, 2025
Maintains: Sector Outperform
Price Target: $73 → $75
Current: $61.10
Upside: +22.75%
Oct 16, 2024
Initiates: Sector Outperform
Price Target: $18
Current: $11.01
Upside: +63.49%
Jun 13, 2023
Maintains: Buy
Price Target: $89 → $91
Current: $11.00
Upside: +727.27%
May 1, 2023
Upgrades: Neutral
Price Target: $9 → $12
Current: $16.91
Upside: -29.04%
Apr 28, 2023
Downgrades: Underperform
Price Target: $5 → $1.5
Current: $0.54
Upside: +177.98%
Mar 7, 2023
Initiates: Buy
Price Target: $39
Current: $13.56
Upside: +187.61%
Nov 18, 2022
Maintains: Neutral
Price Target: $18 → $15
Current: $3.08
Upside: +387.01%
Nov 8, 2022
Downgrades: Underperform
Price Target: $3
Current: $4.27
Upside: -29.74%
Sep 29, 2022
Initiates: Buy
Price Target: $70
Current: $1.54
Upside: +4,445.45%
Mar 16, 2022
Maintains: Buy
Price Target: $67 → $54
Current: $17.19
Upside: +214.14%
Mar 14, 2022
Downgrades: Underperform
Price Target: $270 → $90
Current: $25.72
Upside: +249.92%